GRNA · Greenlight Biosciences Holdings, Pbc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue | $1.59M | - | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| R&D | $89.83M | - | - |
| SG&A | $35.93M | $13.10M | - |
| Total Operating Expenses | $110.15M | - | - |
| D&A | $5.77M | - | - |
| Operating Income | ($163.92M) | ($13.10M) | - |
| Interest Expense | $2.42M | - | - |
| Income Tax | $1.09M | - | - |
| Net Income | ($167.06M) | ($15.06M) | - |
| EPS - Basic | ($1.17) | - | - |
| EPS - Diluted | ($1.17) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash & Equivalents | $68.10M | $67.5K | $156.8K |
| Accounts Receivable | - | - | - |
| Inventory | - | - | - |
| Accounts Payable | $839.0K | - | - |
| Current Assets | $71.31M | $530.0K | - |
| Total Assets | $148.60M | $207.54M | $337.9K |
| Current Liabilities | $35.56M | $12.32M | $315.4K |
| Long-term Debt | - | - | - |
| Total Liabilities | $100.54M | $28.21M | - |
| Stockholders' Equity | $48.06M | ($27.66M) | $22.5K |
| Retained Earnings | ($420.64M) | ($27.66M) | ($2.5K) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Cash Flow | ($136.73M) | ($1.81M) | - |
| Investing Cash Flow | ($26.51M) | ($207.00M) | - |
| Financing Cash Flow | $200.85M | $208.72M | - |
| CapEx | $15.15M | - | - |
| Free Cash Flow | ($151.88M) | - | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | - |
| Operating margin | -10277.1% | - | - |
| EBITDA margin | -9915.2% | - | - |
| Net margin | -10473.7% | - | - |
| Free cash flow margin | -9522.2% | - | - |
| FCF / Net income | 0.91 | - | - |
| R&D / Revenue | 5632.1% | - | - |
| SG&A / Revenue | 2252.7% | - | - |
| Effective tax rate | - | - | - |
| Return on assets | -112.4% | -7.3% | - |
| Return on equity | -347.6% | 54.4% | - |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 2.01 | 0.04 | - |
| Quick ratio | 2.01 | 0.04 | - |
| Cash ratio | 1.91 | 0.01 | 0.50 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | -67.8x | - | - |
| Equity multiplier | 3.09 | -7.50 | 15.04 |
| Liabilities / Assets | 0.68 | 0.14 | - |
| Efficiency | |||
| Asset turnover | 0.01 | - | - |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | - | - |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | - | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | -1151.7% | - | - |
| Net income growth (YoY) | -1009.3% | - | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | - | - | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | - | - | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-5.44
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing GreenLight Biosciences Holdings against the 5 most active filers in the same SIC group.